News | January 11, 2026
PAI Pharma acquires Nivagen to boost US injectable drug production
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The approval is backed by data showing deep, durable responses and manageable tolerability
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Heart failure affects an estimated 64.3 million people worldwide
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
Subscribe To Our Newsletter & Stay Updated
